Standardization and Application of Pure Platelet-Rich Plasma in Improving Sperm Function
NCT ID: NCT07348354
Last Updated: 2026-01-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
248 participants
INTERVENTIONAL
2026-01-22
2027-12-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Aims:
To validate a standardized double-spin protocol for preparing pure platelet-rich plasma (P-PRP) in an IVF laboratory setting by assessing its platelet yield, purity, and reproducibility.
Outcomes
Primary outcome Platelet concentration in PRP Absolute platelet count in P-PRP and fold-increase compared to whole blood Secondary outcome Platelet recovery (%): (Platelet count in P-PRP × P-PRP volume) / (Whole blood platelet count × blood volume) × 100 Purity: White blood cell (WBC) concentration in P-PRP Growth factors :e.g.. VEGF, PDGF-AB, TGF-β, IGF-1… concentrations in plasma of PPP and P-PRP preparation Reproducibility Metrics: Coefficient of variation (CV%), intraclass correlation coefficient (ICC), and Bland-Altman limits of agreement for technical and biological duplicates.
Phase 2: Examine the effect of pure platelet-rich plasma (P-PRP) on sperm parameters Hypotheses and objectives Hypotheses The investigator hypothesizes that co-culture of semen with pure platelet-rich plasma (P-PRP) enhances sperm quality by increasing motility compared to standard culture medium without P-PRP (control group).
Primary outcome
\- To compare total sperm motility after 24 hours of co-culture between semen samples co-cultured with P-PRP versus a control group (without P-PRP).
Secondary outcome
* To compare sperm parameters after other timepoints of co-culture between semen samples co-cultured with P-PRP versus a control group (without P-PRP).
* To compare the morphology and DNA Fragmentation Index (DFI) in semen samples after 24-hour co-culture with P-PRP versus control.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Female Autologous Platelet-Rich Plasma (PRP) Co-incubation With Husband's Sperm
NCT07282327
Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation
NCT05279560
Ovarian PRP Injection in Women With POR
NCT05601193
Ovarian PRP Injections for Improved Embryo Quality Using Embryo Quality Score
NCT07020546
Autologous Platelet-rich Plasma to Improve Responsiveness and Embryo Quality in Patients With Poor Ovarian Response
NCT05105724
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Non-PRP group
Sperm after washing without co-culture
Standard culture
Only sperm culture
PRP group
Sperm after washing with PRP co-culture
PRP culture
PRP 2-5% will be co-culture with sperm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard culture
Only sperm culture
PRP culture
PRP 2-5% will be co-culture with sperm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Adequate sperm samples (raw sample TMS \> 5 x 106)
* BMI \<30 kg/m2
Exclusion Criteria
* Drug addiction
* Underlying uncontrolled genital infections, diabetes or hypertension, chromosomal or uterine abnormalities, genetic, hematologic, immunological, or endocrine disorders
* Chronic disease, systemic disease, or cancers
* Blood diseases (sepsis, thrombocytopenia)
* Do not agree to donate blood
* Use of supplements containing antioxidants within the past 3 months
* Administration of anticoagulants or NSAIDs at least 7 days before P-PRP infuse
* Haemoglobin \< 11g/dL, platelet count \< 150000 mm3
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese University of Hong Kong
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chung Pui Wah Jacqueline
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dr. Chung Pui Wah Jacqueline
Hong Kong, , China
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025.681
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.